Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ArsenalBio develops programmable autologous T cell therapies for solid tumors using a proprietary platform that combines CRISPR-based genome engineering with synthetic DNA circuits to enhance efficacy and safety. The company has advanced at least one program into clinical trials but detailed results are not yet published as of June 2025. Their approach aims to overcome the challenges of treating solid tumors with cell therapies by improving targeting specificity and multifunctionality.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arsenal Barber Co..